Analysts’ Weekly Ratings Changes for ConforMIS (CFMS)

A number of firms have modified their ratings and price targets on shares of ConforMIS (NASDAQ: CFMS) recently:

  • 2/12/2018 – ConforMIS was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “ConforMIS, Inc. is a medical technology company which develops, manufacture and sells joint replacement implants. The Company’s iFit technology platform consists of iFit Design, iFit Printing and iFit Just-in-Time Delivery. It operates primarily in the United States, Germany and the United Kingdom. The Company serves orthopedic surgeons, hospitals and other medical facilities and patients. ConforMIS, Inc. is based in Bedford, United States. “
  • 2/8/2018 – ConforMIS had its price target lowered by analysts at Canaccord Genuity from $5.00 to $4.00. They now have a “hold” rating on the stock.
  • 2/8/2018 – ConforMIS was given a new $4.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 1/24/2018 – ConforMIS was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “ConforMIS, Inc. is a medical technology company which develops, manufacture and sells joint replacement implants. The Company’s iFit technology platform consists of iFit Design, iFit Printing and iFit Just-in-Time Delivery. It operates primarily in the United States, Germany and the United Kingdom. The Company serves orthopedic surgeons, hospitals and other medical facilities and patients. ConforMIS, Inc. is based in Bedford, United States. “
  • 1/10/2018 – ConforMIS had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $4.00 price target on the stock.
  • 1/2/2018 – ConforMIS was downgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “underweight” rating.
  • 12/20/2017 – ConforMIS was upgraded by analysts at BTIG Research from a “neutral” rating to a “buy” rating. They now have a $4.00 price target on the stock.

ConforMIS Inc (NASDAQ CFMS) opened at $1.46 on Wednesday. ConforMIS Inc has a 1 year low of $1.15 and a 1 year high of $8.61. The company has a debt-to-equity ratio of 0.52, a quick ratio of 5.38 and a current ratio of 6.19. The stock has a market cap of $66.13 and a P/E ratio of -1.18.

ConforMIS (NASDAQ:CFMS) last posted its quarterly earnings results on Wednesday, February 7th. The medical instruments supplier reported ($0.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.03. The company had revenue of $20.80 million during the quarter, compared to analyst estimates of $20.07 million. ConforMIS had a negative net margin of 68.59% and a negative return on equity of 78.44%. ConforMIS’s revenue for the quarter was down 4.1% compared to the same quarter last year. During the same period last year, the firm posted ($0.37) EPS. equities analysts predict that ConforMIS Inc will post -0.86 earnings per share for the current fiscal year.

In other news, CEO Mark A. Augusti sold 16,548 shares of ConforMIS stock in a transaction that occurred on Tuesday, December 19th. The shares were sold at an average price of $2.27, for a total transaction of $37,563.96. Following the completion of the transaction, the chief executive officer now directly owns 285,007 shares of the company’s stock, valued at approximately $646,965.89. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Over the last ninety days, insiders have sold 43,691 shares of company stock valued at $91,154. Insiders own 9.55% of the company’s stock.

ConforMIS, Inc is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints.

Receive News & Ratings for ConforMIS Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply